Heartbeam Inc - BEAT STOCK NEWS

HeartBeam (NASDAQ: BEAT) has appointed Dr. Lance Myers as Chief AI Scientist to drive innovation in its cardiac care technology. Dr. Myers, formerly Head of Data Science at Verily (Google Life Sciences), will guide AI application to HeartBeam's core technology. The company's vector-based approach combined with AI has shown equivalent performance to a 12-lead ECG and improved detection of atrial flutter over single-lead ECG.

HeartBeam's technology captures heart signals in three dimensions, with its first application being a cable-free, credit card-sized device capable of synthesizing a 12-lead ECG. The system is under FDA review. The company aims to leverage AI for improved diagnostic accuracy and personalized cardiac care, analyzing longitudinal data from patient device usage.

HeartBeam (NASDAQ: BEAT) has appointed Timothy Cruickshank as its new Chief Financial Officer, effective immediately. Cruickshank brings over 15 years of public company experience, focusing on growing businesses with disruptive technologies. He succeeds Richard Brounstein, who retired in February.

HeartBeam has developed a cable-free, credit card-sized device that captures the heart's electrical signals in three dimensions, capable of synthesizing a 12-lead ECG. The company's first 510(k) submission for this proprietary technology is currently under FDA review. HeartBeam holds 13 US patents and 4 international patents supporting the technology.

Cruickshank, 43, previously served as CFO at ImpediMed, where he led the company's transformation from a traditional medical device company to a medical technology company with a high-margin SaaS business model.

HeartBeam (NASDAQ: BEAT) reported Q2 2024 results, highlighting progress on its HeartBeam AIMIGo™ System. Key developments include:

1. FDA review of AIMIGo 510(k) submission ongoing, with most questions resolved.
2. Completed enrollment for VALID-ECG clinical study.
3. Presented new data on HeartBeam AI at EHRA and HRS conferences.
4. Won 'Best New ECG Technology Solution' award.
5. Added to Russell Microcap® Index.

Financial results: R&D expenses $2.8M, G&A expenses $2.2M, net loss $5.0M. Cash position: $9.2M as of June 30, 2024. The company anticipates FDA clearance and AIMIGo launch by end of 2024.

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has announced its upcoming second quarter 2024 results conference call. The call is scheduled for Wednesday, August 14, 2024, at 4:30 p.m. Eastern time. CEO Branislav Vajdic, President Robert Eno, and Senior Director & Corporate Controller Ravi Malhotra will host the call, which will include discussions on Q2 results, regulatory updates, ongoing initiatives, and anticipated 2024 milestones.

A press release detailing the results will be issued before the call. Investors can access the call via phone or webcast, with a presentation available during the webcast and on the company's investor relations website. A replay of the call will be available until November 14, 2024.

HeartBeam, a medical technology company specializing in cardiac care, announced its addition to the Russell Microcap® Index. This inclusion is effective post-market close on June 28, 2024, following the FTSE Russell’s annual reconstitution, which ranks the 4,000 largest US stocks by market capitalization as of April 30. Being part of the Russell Microcap® Index, which lists the smallest 1,000 securities in the Russell 2000® Index plus the next 1,000 smallest eligible securities, provides HeartBeam with enhanced visibility and potential accessibility to $10.5 trillion in assets benchmarked against these indexes. The Russell indexes serve as key benchmarks for investment managers and institutional investors.

Epitel, a pioneer in AI-powered brain health solutions, has announced the appointment of Ken Nelson to its Board of Directors. Nelson, an expert in digital health and remote patient monitoring, brings over 20 years of experience to Epitel. He has held key positions in leading companies such as BioTelemetry, iRhythm, and Bardy Diagnostics, with notable achievements including BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter. As Epitel strives to revolutionize brain monitoring with AI and wearable EEG technology, Nelson's strategic insight is expected to drive the company's growth and commercial success. He currently holds influential positions in several MedTech startups and advisory boards.

HeartBeam (NASDAQ: BEAT) announced new study data showing that its AI algorithm combined with vectorcardiography (VCG) outperformed expert cardiologists in detecting atrial flutter, a common arrhythmia. The study, presented at the Heart Rhythm Society annual meeting, involved 173 VCGs, single-lead ECGs, and 12-lead ECGs. Key findings revealed a 40% improvement in detection sensitivity compared to single-lead ECGs reviewed by cardiologists and a 6% improvement over 12-lead ECGs. HeartBeam's core technology captures heart signals in three projections, aiming for a more personalized cardiac care approach. Their AIMIGo™ device, for patient use, is under FDA review.

HeartBeam, Inc. (NASDAQ: BEAT) has won the 'Best New ECG Technology Solution' award in the 8th annual MedTech Breakthrough Awards for their HeartBeam AIMIGo™ device. The AIMIGo™ device is a credit card-sized tool that allows for remote evaluation of cardiac symptoms, capturing heart signals in three projections and synthesizing them into a 12-lead ECG. The device is currently under FDA review and aims to provide a personalized approach to cardiac care outside of medical facilities.

HeartBeam, Inc. (NASDAQ: BEAT) reported positive results for its AIMIGo™ 3D VECG system, showcasing progress in clinical and regulatory milestones. The company anticipates FDA clearance by Q2 2024 for the AIMIGo system and plans for a launch by 2024 end. The VALID-ECG pivotal study for the 12-Lead Synthesis Software submission is underway, aiming to demonstrate similarity with a standard 12-lead ECG. HeartBeam AI showed improved performance in detecting arrhythmias, supported by new patents and positive data presented at EHRA conference. Cash and cash equivalents stood at approximately $12.6 million as of March 31, 2024, enabling future clinical and regulatory milestones.